{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:07:05Z","timestamp":1784804825550,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T00:00:00Z","timestamp":1523836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T00:00:00Z","timestamp":1523836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["#17ek01091490003"],"award-info":[{"award-number":["#17ek01091490003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00535-018-1465-z","type":"journal-article","created":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T11:08:35Z","timestamp":1523876915000},"page":"1151-1158","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study"],"prefix":"10.1007","volume":"53","author":[{"name":"Japan PBC Study Group (JPBCSG)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minami","family":"Yagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6358-5283","authenticated-orcid":false,"given":"Atsushi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Namisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromasa","family":"Ohira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Yoshiji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Takikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,16]]},"reference":[{"issue":"12","key":"1465_CR1","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1056\/NEJMra043898","volume":"353","author":"MM Kaplan","year":"2005","unstructured":"Kaplan MM, Gershwin ME. Primary biliary cirrhosis. New Engl J Med. 2005;353(12):1261\u201373.","journal-title":"New Engl J Med."},{"issue":"1","key":"1465_CR2","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/hep.22906","volume":"50","author":"KD Lindor","year":"2009","unstructured":"Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology. 2009;50(1):291\u2013308.","journal-title":"Hepatology"},{"issue":"4","key":"1465_CR3","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1542-3565(03)00134-4","volume":"1","author":"JA Talwalkar","year":"2003","unstructured":"Talwalkar JA, Souto E, Jorgensen RA, et al. Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2003;1(4):297\u2013302.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"1465_CR4","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/apt.13794","volume":"44","author":"JK Dyson","year":"2016","unstructured":"Dyson JK, Wilkinson N, Jopson L, et al. The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis. Aliment Pharmacol Ther. 2016;44(10):1039\u201350.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1465_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/hep.26365","volume":"58","author":"GF Mells","year":"2013","unstructured":"Mells GF, Pells G, Newton JL, et al. Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study. Hepatology. 2013;58(1):273\u201383.","journal-title":"Hepatology"},{"issue":"4","key":"1465_CR6","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jhep.2005.12.012","volume":"44","author":"JL Newton","year":"2006","unstructured":"Newton JL, Bhala N, Burt J, et al. Characterisation of the associations and impact of symptoms in primary biliary cirrhosis using a disease specific quality of life measure. J Hepatol. 2006;44(4):776\u201383.","journal-title":"J Hepatol"},{"issue":"1","key":"1465_CR7","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/hep.26909","volume":"60","author":"U Beuers","year":"2014","unstructured":"Beuers U, Kremer AE, Bolier R, et al. Pruritus in cholestasis: facts and fiction. Hepatology. 2014;60(1):399\u2013407.","journal-title":"Hepatology"},{"key":"1465_CR8","first-page":"CD000551","volume":"12","author":"JS Rudic","year":"2012","unstructured":"Rudic JS, Poropat G, Krstic MN, et al. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev. 2012;12:CD000551.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"1465_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","volume":"51","author":"EASL","year":"2009","unstructured":"EASL. EASL Clinical practice guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51(2):237\u201367.","journal-title":"J Hepatol"},{"issue":"Suppl S1","key":"1465_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/hepr.12270","volume":"44","author":"Working Subgroup for Clinical Practice Guidelines for Primary Biliary Cirrhosis","year":"2014","unstructured":"Working Subgroup for Clinical Practice Guidelines for Primary Biliary Cirrhosis. Guidelines for the management of primary biliary cirrhosis: the intractable hepatobiliary disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan. Hepatol Res. 2014;44(Suppl S1):71\u201390.","journal-title":"Hepatol Res."},{"issue":"2","key":"1465_CR11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.cld.2008.02.013","volume":"12","author":"NV Bergasa","year":"2008","unstructured":"Bergasa NV. Pruritus in primary biliary cirrhosis: pathogenesis and therapy. Clin Liver Dis. 2008;12(2):385\u2013406.","journal-title":"Clin Liver Dis"},{"issue":"2","key":"1465_CR12","first-page":"295","volume":"91","author":"NV Bergasa","year":"1996","unstructured":"Bergasa NV, Jones A, Kleiner DE, et al. Pilot study of low dose oral methotrexate treatment for primary biliary cirrhosis. Am J Gastroenterol. 1996;91(2):295\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"1465_CR13","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1093\/ndt\/gfp588","volume":"25","author":"H Kumagai","year":"2010","unstructured":"Kumagai H, Ebata T, Takamori K, et al. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant. 2010;25(4):1251\u20137.","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"1465_CR14","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1111\/hepr.12830","volume":"47","author":"H Kumada","year":"2017","unstructured":"Kumada H, Miyakawa H, Muramatsu T, et al. Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: a randomized, double-blind trial. Hepatol Res. 2017;47(10):972\u201382.","journal-title":"Hepatol Res."},{"issue":"1","key":"1465_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/hepr.12894","volume":"48","author":"N Akuta","year":"2018","unstructured":"Akuta N, Kumada H, Fujiyama S, et al. Predictors of pruritus in patients with chronic liver disease and usefulness of nalfurafine hydrochloride. Hepatol Res. 2018;48(1):45\u201350.","journal-title":"Hepatol Res."},{"issue":"4","key":"1465_CR16","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/hep.25748","volume":"56","author":"AE Kremer","year":"2012","unstructured":"Kremer AE, van Dijk R, Leckie P, et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology. 2012;56(4):1391\u2013400.","journal-title":"Hepatology"},{"key":"1465_CR17","unstructured":"Yagi M, Tanaka A, Abe M, et al. Symptoms and health-related quality of life in Japanese patients with primary biliary cholangitis. Submitted."},{"key":"1465_CR18","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2957\/kanzo.57.457","volume":"57","author":"A Tanaka","year":"2016","unstructured":"Tanaka A, Miura K, Yagi M, et al. The assessment of subjective symptoms and patient-reported outcomes in patients with primary biliary cholangitis using PBC-40. Kanzo [in Japanese]. 2016;57:457\u201367.","journal-title":"Kanzo [in Japanese]."},{"issue":"11","key":"1465_CR19","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1136\/gut.2005.065862","volume":"54","author":"A Jacoby","year":"2005","unstructured":"Jacoby A, Rannard A, Buck D, et al. Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis. Gut. 2005;54(11):1622\u20139.","journal-title":"Gut"},{"key":"1465_CR20","volume-title":"Quality of life and pharmacoeconomics in clinical trials","author":"JEJ Ware","year":"1996","unstructured":"Ware JEJ. The SF-36 health survey. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven; 1996.","edition":"2"},{"issue":"11","key":"1465_CR21","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S0895-4356(98)00095-X","volume":"51","author":"S Fukuhara","year":"1998","unstructured":"Fukuhara S, Bito S, Green J, et al. Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol. 1998;51(11):1037\u201344.","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"1465_CR22","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S0895-4356(98)00096-1","volume":"51","author":"S Fukuhara","year":"1998","unstructured":"Fukuhara S, Ware JE Jr, Kosinski M, et al. Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol. 1998;51(11):1045\u201353.","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"1465_CR23","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.autrev.2016.03.019","volume":"15","author":"Y Sun","year":"2016","unstructured":"Sun Y, Zhang W, Evans JF, et al. Autotaxin, pruritus and primary biliary cholangitis (PBC). Autoimmun Rev. 2016;15(8):795\u2013800.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"1465_CR24","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1053\/j.gastro.2010.05.009","volume":"139","author":"AE Kremer","year":"2010","unstructured":"Kremer AE, Martens JJ, Kulik W, et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology. 2010;139(3):1008\u201318.","journal-title":"Gastroenterology"},{"issue":"Supplement 1","key":"1465_CR25","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S0168-8278(10)00232-1","volume":"52","author":"AE Kremer","year":"2010","unstructured":"Kremer AE, Martens JJ, Kulik W, et al. Autotaxin but not bile salts correlate with itch intensity in cholestasis. J Hepatol. 2010;52(Supplement 1):S1.","journal-title":"J Hepatol"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-018-1465-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-018-1465-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-018-1465-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T09:38:40Z","timestamp":1589449120000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-018-1465-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,16]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["1465"],"URL":"https:\/\/doi.org\/10.1007\/s00535-018-1465-z","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,16]]},"assertion":[{"value":"7 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AT received consultant fees from EA Pharma and GlaxoSmithKline. YM received lecture fees from Mitsubishi Tanabe Pharma, MSD K.K., AbbVie GK, Gilead Science, Janssen Pharmaceutical K.K. and commercial research findings from MSD K.K., AbbVie GK, Gilead Science, and Nobelpharma, Eisai Co.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}